Novo Nordisk reported top-line results from the Phase III PIONEER 6 trial showing that oral semaglutide achieved an encouraging but non-significant reduction in major adverse cardiovascular events (MACE), including a robust decrease in death yet an increase in non-fatal myocardial infarction (MI).

To provide FirstWord readers with rapid feedback, we are hosting an expert call with a key opinion leader (KOL) this week.

Key topics that will be discussed during the call include, among other things… feedback on the PIONEER 6 results; are you disappointed that oral semaglutide did not hit significance on MACE; how does the 21-percent reduction versus placebo match up with your expectations going in; thoughts on its 51-percent reduction in cardiovascular mortality and 18-percent increase in non-fatal MI; is the massive disparity in specific outcomes good or bad; do these results raise or lower your opinion of semaglutide; will they have any impact on use of the agent; and on a related note, do you think the PIONEER 6 data (perhaps supported by SUSTAIN 6) will be sufficient for Novo Nordisk’s Ozempic (semaglutide)?

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.